In a prospective analysis, 105 patients with standard-risk acute leukemia (AML, ALL or MDS) were MRD positive after allo-SCT—of which, 49 received low-dose IL-2 only, and 56 modified DLI, with or without low-dose IL-2. This evidence concerns the gene IL2 and acute myeloid leukemia.